Aurinia Pharmaceuticals Inc (TSE:AUP) (NASDAQ:AUPH) – Cantor Fitzgerald decreased their FY2017 earnings per share (EPS) estimates for shares of Aurinia Pharmaceuticals in a report released on Monday. Cantor Fitzgerald analyst E. Piros now anticipates that the company will post earnings per share of ($1.35) for the year, down from their previous forecast of ($1.27). Cantor Fitzgerald also issued estimates for Aurinia Pharmaceuticals’ FY2018 earnings at ($0.97) EPS.
Separately, Seaport Global Securities reiterated a “buy” rating on shares of Aurinia Pharmaceuticals in a research report on Friday, October 6th.
Aurinia Pharmaceuticals Company Profile
Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.
What are top analysts saying about Aurinia Pharmaceuticals Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Aurinia Pharmaceuticals Inc and related companies.